X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs CIPLA - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA CIPLA GLENMARK PHARMA/
CIPLA
 
P/E (TTM) x 19.9 37.7 52.9% View Chart
P/BV x 3.6 3.9 92.0% View Chart
Dividend Yield % 0.3 0.3 102.2%  

Financials

 GLENMARK PHARMA   CIPLA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-17
CIPLA
Mar-17
GLENMARK PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs993622 159.7%   
Low Rs729458 159.1%   
Sales per share (Unadj.) Rs325.5181.9 179.0%  
Earnings per share (Unadj.) Rs39.312.9 305.3%  
Cash flow per share (Unadj.) Rs48.729.3 166.0%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.20.4 62.7%  
Book value per share (Unadj.) Rs159.2155.7 102.3%  
Shares outstanding (eoy) m282.17804.51 35.1%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.63.0 89.1%   
Avg P/E ratio x21.942.0 52.2%  
P/CF ratio (eoy) x17.718.4 96.0%  
Price / Book Value ratio x5.43.5 155.9%  
Dividend payout %5.115.5 32.8%   
Avg Mkt Cap Rs m242,991434,516 55.9%   
No. of employees `00013.023.0 56.3%   
Total wages/salary Rs m16,40826,338 62.3%   
Avg. sales/employee Rs Th7,083.96,349.1 111.6%   
Avg. wages/employee Rs Th1,265.41,143.0 110.7%   
Avg. net profit/employee Rs Th855.1449.3 190.3%   
INCOME DATA
Net Sales Rs m91,857146,302 62.8%  
Other income Rs m3742,287 16.3%   
Total revenues Rs m92,230148,589 62.1%   
Gross profit Rs m20,36724,758 82.3%  
Depreciation Rs m2,64413,229 20.0%   
Interest Rs m2,3731,594 148.9%   
Profit before tax Rs m15,72412,222 128.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m-8100-   
Tax Rs m3,8271,798 212.9%   
Profit after tax Rs m11,08810,354 107.1%  
Gross profit margin %22.216.9 131.0%  
Effective tax rate %24.314.7 165.5%   
Net profit margin %12.17.1 170.6%  
BALANCE SHEET DATA
Current assets Rs m68,74687,370 78.7%   
Current liabilities Rs m27,02733,081 81.7%   
Net working cap to sales %45.437.1 122.4%  
Current ratio x2.52.6 96.3%  
Inventory Days Days8587 97.8%  
Debtors Days Days9662 153.3%  
Net fixed assets Rs m24,132111,567 21.6%   
Share capital Rs m2821,609 17.5%   
"Free" reserves Rs m44,643123,645 36.1%   
Net worth Rs m44,925125,254 35.9%   
Long term debt Rs m45,36336,454 124.4%   
Total assets Rs m117,639209,532 56.1%  
Interest coverage x7.68.7 88.0%   
Debt to equity ratio x1.00.3 347.0%  
Sales to assets ratio x0.80.7 111.8%   
Return on assets %11.45.7 200.7%  
Return on equity %24.78.3 298.6%  
Return on capital %19.18.5 225.3%  
Exports to sales %034.2 0.0%   
Imports to sales %08.3 0.0%   
Exports (fob) Rs mNA50,050 0.0%   
Imports (cif) Rs mNA12,203 0.0%   
Fx inflow Rs m56,15251,066 110.0%   
Fx outflow Rs m8,08417,678 45.7%   
Net fx Rs m48,06833,388 144.0%   
CASH FLOW
From Operations Rs m6,57423,824 27.6%  
From Investments Rs m-7,124-13,127 54.3%  
From Financial Activity Rs m5,432-13,239 -41.0%  
Net Cashflow Rs m1,992-2,478 -80.4%  

Share Holding

Indian Promoters % 48.3 16.0 301.9%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 6.9 12.2 56.6%  
FIIs % 34.4 23.7 145.1%  
ADR/GDR % 0.0 1.1 -  
Free float % 10.5 26.2 40.1%  
Shareholders   56,727 161,166 35.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  BIOCON LTD  PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare GLENMARK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Rising Oil Prices; RBI Minutes and Top Stocks in Action Today(Pre-Open)

Indian share markets surged on Wednesday, snapping a two-day losing streak led by gains Reliance Industries and bank stocks.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.6%

May 31, 2018 | Updated on May 31, 2018

For the quarter ended March 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 6.6% YoY). Sales on the other hand came in at Rs 23 bn (down 7.2% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

CIPLA Announces Quarterly Results (4QFY18); Net Profit Down 347.8%

May 24, 2018 | Updated on May 24, 2018

For the quarter ended March 2018, CIPLA has posted a net profit of Rs 2 bn (down 347.8% YoY). Sales on the other hand came in at Rs 37 bn (up 3.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Jun 20, 2018 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - FDC LTD. COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS